Published 3 months ago

GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests - GSK (NYSE:GSK)

Summary by Benzinga

Scientists have discovered that the shingles vaccine Shingrix, developed by GSK Plc (NYSE:GSK), may reduce the risk of dementia, a finding that could significantly impact public health. The research, published in Nature Medicine, showed that individuals vaccinated with Shingrix lived an average of 164 days longer without a dementia diagnosis compared to those who received the older Zostavax vaccine. Related: GSK Says Its Blockbuster Shingles Vac…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated3 months agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

GSK's Top Selling Vaccine Can Potentially Reduce Dementia Risk, Research Suggests - GSK (NYSE:GSK)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics